Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You really think Ronin will tell them anything anymore.
They came out with their statement how they would get PPHM back on track and low and behold PPHM BOD does it and tries to take credit for it.
Their next step wont be handed to them.
Probably just a YOUR FIRED SIP will be, just like they gave the 60 workers before bringing in the new sham people.
Here are some facts I dont have the Watson just a HP so it took me a little longer
The interest misalignment also appears to extend to Peregrine's management team. Steven W. King (CEO) and Paul J. Lytle (CFO) have each been at the Company for 20 years. Despite their long tenure, combined they own outright less than 0.14% of the Company. Peregrine's five named executive officers ("NEO's") own outright a combined 93,467 shares of the Company, a mere 0.21% stake!6 While the NEO's have been granted over 1 million options,7 only a fraction of those options are in-the-money, leaving them with a minimal vested financial interest.
Most recently, on April 28, 2017, Messrs. King and Lytle and Joseph S. Shan (Vice President) each filed Form 4's indicating purchases of 19,941 shares, 37,389 shares and 39,177 shares, respectively.8 Even though these shares were purchased on April 28th, a day on which Peregrine's stock closed at $0.6156 per share, these insiders purchased their shares for $0.2712 per share, giving them an instant gain of over 125%. How was this possible?
Messrs. King, Lytle and Shan purchased their shares through Peregrine's Employee Stock Purchase Plan, which gives certain insiders a six month look-back window (the two windows ending October 31st and April 30th) to purchase stock at 85% of the fair market value on either the first or last day of the window. With April 28th being the final trading day of the window, insiders were allowed to purchase stock at 85% of the price of Peregrine's shares on either April 28, 2017 or November 1, 2016. Accordingly, despite the price of Peregrine's stock rising materially from its close of $0.319 per share on November 1, 2016, Peregrine insiders were able to purchase stock from the Company on April 28, 2017 at 85% of the price of Peregrine shares six months ago (i.e. $0.2712 per share).
Peregrine's Employee Stock Purchase Plan, which allows management to profit at the direct expense of stockholders, is yet another example of the misalignment of interests and the cultural leadership plague that has harmed Peregrine's stockholders. Management being allowed to profit directly at stockholders' expense is insulting. We believe these purchases are unfair, dilutive and fail to properly incentivize management.
Independent Directors Lack Relevant Experience
It appears that not one of the three independent directors possess ANY experience, no matter how tangential, in either contract manufacturing or biotechnology.
Mr. Pohl is a semi-retired attorney who serves as Of Counsel for Herold & Sager, a small law firm based in California. Although his area of practice for Herold & Sager is not described, his bio for Peregrine notes that he previously worked as general counsel for large financial services companies. He has served as a director on one other public board – a company without any revenues in its history that has unsuccessfully attempted to license semiconductor technology. Mr. Pohl does not appear to have any experience whatsoever with biotechnology or contract manufacturing.
Mr. Swartz is a financier who was most recently registered as a broker for NMS Capital Advisors LLC for one year, ending in 2016, according to FINRA records. We were unable to find any recent activity with the various investment entities that he owns and manages (as described further in the section below). Mr. Swartz does not appear to have any experience of any kind with biotechnology or contract manufacturing, nor does he have any public board experience outside of Peregrine.
Mr. Johnson is a self-employed attorney, although he is also described as having been a stockholder of the law firm of Smith, Sauer, DeMaria, Johnson out of Florida. Although various websites describe this firm's specialty as "elder care," oddly, no website exists for the firm. None of Mr. Johnson's biographical information suggests any background in biotechnology or contract manufacturing. He has served on three other public company boards, none of which relate to biotechnology or contract manufacturing.
Despite their apparent lack of relevant experience, these directors somehow annually make hundreds of thousands of dollars more for their service on Peregrine's Board than their counterparts who serve as directors of the hundred-billion dollar pharmaceutical firms noted above.
Independent Directors Have Records of Value Destruction and Questionable Dealings
In addition to the severe interest misalignment with stockholders and absence of relevant experience to Peregrine's businesses, the involvement with public companies that Messrs. Johnson, Pohl and Swartz do have is characterized by shockingly consistent failure and stockholder value destruction that should deeply concern all Peregrine stockholders.
Mr. Pohl currently serves on the advisory board of Max Sound Corp. ("Max Sound"), a $2.0 million market cap company with a stock price of roughly $0.002 per share and no revenue in the company's history.9 Mr. Pohl joined Max Sound's advisory board in August 2014 with a grandiose press release describing him as a "famed attorney" joining Max Sound's self-proclaimed "prestigious" advisory board. Mr. Pohl joined the advisory board despite possessing no identifiable background in the type of audio "disruptive technology" that Max Sound claims to own (and has unsuccessfully tried to sue companies like Google for royalties). Shares of Max Sound have lost nearly 99% of their value since Mr. Pohl joined the company.
Mr. Pohl's only other public company experience was serving as a director of Patriot Scientific Corp. ("Patriot Scientific"), a $5.6 million market cap company with a stock price of roughly $0.014 per share,10 from 2001-2008, while also serving as its CEO from 2005-2007. Patriot Scientific (where Mr. Johnson has also served as a director since 2001), like Max Sound, is a failed intellectual property company that has not generated any material revenue in the life of the company and has had zero revenues since 2010. Since 2001, Patriot Scientific's stock has lost roughly 94% of its value.
Mr. Swartz is the founder, principal and/or manager of several financial firms including Roswell Capital Partners, LLC, Equiplace Securities, LLC, Swartz Investments, LLC, BridgePointe Master Fund Ltd. and Centurion Private Equity, LLC (collectively, the "Roswell entities"). These are a mix of related finance and investment vehicles managed by Mr. Swartz, and they have been involved with raising capital for questionable pink sheet stocks since the mid-1990s.
According to his Peregrine biography, Mr. Johnson worked for Mr. Swartz since at least 1996, acting as in-house legal counsel for Roswell Capital affiliated entities until becoming "self-employed" in 2013. Mr. Johnson has also served as a director of Patriot Scientific since August 2001 (where Mr. Pohl previously served as a director and CEO as noted above), during which time its fully diluted share count has increased by roughly 650% while its stock has lost approximately 94% of its value. Mr. Johnson previously served as a director of Cryoport, Inc. from 2009-2012,11 during which time the stock lost 84% of its value while the fully diluted share count increased by over 800%. He also previously served as a director of ECOtality, Inc. from 2009-2011,12 during which time the stock lost 90% of its value while the fully diluted share count increased by over 500%, with the company later filing for bankruptcy in 2013.
Unfortunately, Messrs. Swartz's and Johnson's track record with failed and highly questionable companies at the Roswell entities is so long that for the sake of brevity we are limited to providing a partial list of the penny stock companies and a very brief description of the relevant outcomes for stockholders. According to public records, below is a limited list of public companies which Messrs. Swartz and Johnson have provided (or attempted to provide) financing to and have generally been involved with.
Date of Announcement
Split-Adjusted Stock Price at Time of First Involvement
Announced Capital Investment
Stock Performance (Rounded)
Note
Company
Alternate Energy Holdings
November 2010
$0.690
$150 million
-100%
Bankrupt; CEO and CFO convicted of fraud
MabCure
January 2011
$0.430
$10 million
-100%
Trades for $0.003 per share
Medisafe 1 Technologies
February 2011
$0.170
$5 million
-100%
Delisted
Diadem Resources
March 2011
$0.090
$8 million
-100%
Delisted
Minerco Resources Inc
December 2010
$0.009
$5 million
-100%
Trades for $0.0022 per share
Clean Power Concepts
April 2011
$0.110
$7.2 million
-100%
Trades for $0.0001 per share
Amarantus BioSciences Inc
October 2011
$0.161
$30 million
-100%
Trades for $0.05 per share
Green EnviroTech Holdings
March 2011
$0.640
$10 million
-100%
Trades for $0.05 per share
DC Brands International
February 2011
$0.075
$5 million
-100%
Delisted
Prominex Resource Corp
February 2011
$0.060
$20 million
-100%
Delisted
Conway Resources
March 2011
$0.080
5 million CAD
-100%
Delisted
WinSonic Digital Media
August 2010
$0.040
$10 million
-100%
Delisted
ICP Solar Technologies
June 2008
$0.670
$5 million
-100%
Delisted
Gopher Protocall
June 2011
$0.120
$10 million
-100%
Delisted
LI3 Energy Inc
December 2010
$0.230
$10 million
-91%
$10 million market cap
Novation Holdings Inc
August 2011
$0.570
$30 million
-100%
Trades for $0.0001 per share
Source: SEC filings; press releases.
While the value destruction speaks for itself, even more troubling is that many of these companies appear to follow a disturbing pattern: pink sheet stocks trading for pennies, no history of revenues or business activities, large reverse-splits, frequent changes to the company's name, a flurry of highly promotional press releases and paid promotional campaigns and stocks which collapsed in a short amount of time after raising capital, eventually being delisted. We have been hard-pressed to find a single stock which the Roswell entities raised capital for that did not resemble one of these extremely troubling fact patterns.
Typically, the Roswell entities provided "equity funding facilities" that allowed highly questionable companies to issue soon-to-be-worthless stock to the general public. Importantly, the Roswell entities were merely acting as a conduit to raise money for such companies, and were not actually investing capital into them. In fact, most of these equity funding facilities permitted the Roswell entities to short the stocks before purchasing discounted shares from the company, effectively allowing the Roswell entities to lock in a profit at the expense of the public without making any investment in the companies. There is no shortage of other unsettling public company dealings from the Roswell entities, which we can detail in future communications.
We believe it is EXTREMELY inappropriate to allow people who appear to be consistently associated with stockholder value destruction to be entrusted as fiduciaries in ANY capacity at ANY public company. The stockholders of Peregrine deserve a Board comprised of highly-qualified independent directors with relevant industry experience and track records of creating stockholder value. Instead, the current Board consists of individuals with track records of value destruction and questionable dealings that cast immense doubt on their ability to act in stockholders' best interests.
ISS Has Previously Recommended WITHHOLD Votes Against ALL Independent Directors
Based on the results from last year's annual meeting, where every independent director received at least 30% WITHHOLD votes with respect to their re-election, it is clear that we are not the only ones who are extremely displeased with the composition of the Board and ready for immediate change. In addition, leading independent proxy advisory firm Institutional Shareholder Services (ISS) recommended a WITHHOLD vote with respect to each of Peregrine's directors, stating:
"WITHHOLD votes are warranted for compensation committee members Carlton M. Johnson Jr., David H. Pohl, and Eric S. Swartz due to continued problematic pay practices and the board's failure to adequately respond to shareholder concerns."
In fact, ISS has recommended WITHHOLD votes against ALL independent directors at each of the past THREE annual meetings. While change is desperately needed at Peregrine, the incumbents appear committed to a pattern of entrenchment. In fact, we are concerned that the Company may have deliberately taken action to frustrate our nomination of director candidates, including by closing its transfer books for an extended period of time.
The status quo, as evidenced by the outrageous equity dilution and abysmal corporate governance practices, has proven untenable, which is why we have formally nominated three independent, highly-qualified candidates, Gregory P. Sargen, Brian W. Scanlan and Saiid Zarrabian, for election at the upcoming 2017 Annual Meeting. In the 16 months since bavituximab's failure of its Phase III SUNRISE trial, the Board has failed to address the Company's problems, and instead, stockholders continue to be diluted at a preposterous rate. We believe the individuals we have nominated possess the financial, operational and strategic acumen the Board urgently needs to enhance stockholder value.
Our Director Nominees: Qualified, Successful, Independent
Gregory P. Sargen ("Greg") is the former Chief Financial Officer and currently the Executive Vice President of Corporate Development of Cambrex Corp. ("Cambrex"), a $1.9 billion market capitalization contract manufacturing organization headquartered in Rutherford, New Jersey. In 2017, Cambrex received 24 awards at the CMO Leadership Awards, for capabilities compatibility, development, expertise, quality, and reliability. During the period of Greg's role as CFO (February 2002 – January 2017), Cambrex's stock price increased approximately 400%, a 17.7% annualized return for stockholders over a 15-year period. As CFO, Greg played a key role in overseeing Cambrex's revenue growth of over 100% and its earnings per share growth of over 650%. Greg has a track record of executive leadership, strong stockholder returns, and excellent experience within the advanced pharmaceutical ingredients (API) contract manufacturing industry. Greg received a bachelor's degree from Penn State University and an MBA from the Wharton School of the University of Pennsylvania.
Brian W. Scanlan ("Brian") is Managing Partner of Freedom Bioscience Partners, LLC, a pharmaceutical services business advisory firm providing direct, dedicated senior leadership support, strategic direction and industry expertise. Brian also currently serves as a director of Callery, LLC, a spin-off of BASF that is a global leader in highly reactive chemistries. From March 2011 to October 2013, Brian served as President and Chief Executive Officer of Cambridge Major Laboratories, Inc. ("CML") (n/k/a Alcami Corporation), a leading global chemistry outsourcing provider of integrated drug development and manufacturing services to the pharmaceutical and biotechnology industries. Brian initially joined CML in 2002 and held various leadership positions prior to becoming President and Chief Executive Officer, including Chief Business Officer, Vice President – Corporate Development, Vice President – Business Development and Director – Sales & Marketing. He also served on the Board of Directors of CML from 2007 to June 2014. Prior to joining CML, Brian served as Manager of Business Development at Rhodia ChiRex Inc., a multinational technology and custom pharmaceutical development and manufacturing firm, from 2000 to 2002. From 1998 to 2000, Brian served as Manager of Sales & Marketing at Universal Pharma Technologies, LLC, a premiere innovator, developer and supplier of pharmaceutical manufacturing equipment and technologies focused on accelerating drug development. Brian began his career in 1991 as a Research Chemist at UOP LLC (n/k/a Honeywell UOP), the leading international supplier and technology licensor for the petroleum refining, gas processing, petrochemical production and major manufacturing industries, after which he led marketing efforts for UOP's Specialty Chemicals Group from 1995 to 1998. Brian earned his MBA from the Illinois Institute of Technology and a B.S. in Chemistry from Northern Illinois University.
Saiid Zarrabian ("Saiid") has nearly 40 years of board and executive/operational experience in multiple industries, including 23 years experience in the biotech, pharmaceutical & instrumentation industries. He currently serves as an advisor to Redline Capital Partners, S.A., a Luxembourg based biotechnology and pharmaceuticals focused investment firm. Saiid has been involved in multiple turnaround situations, including most recently as Chairman of the Board of La Jolla Pharmaceutical Company during the company's transition from an OTC-traded penny stock company to a NASDAQ-listed company with a successful phase three drug. He previously served as CEO, President and a director of Cyntellect, Inc. (2010 – 2012), a stem cell processing and visualization instrumentation company, where he led the company's annual revenue growth from $800,000 to $11 million, culminating in a sale of the company in 2012. Some of Saiid's notable engagements include serving as a consultant/acting COO for SciTegic, Inc. (2002 – 2004), an informatics company with 10X revenue growth culminating in a sale of the company at >35X invested capital within 2.5 years of his engagement; a director of eMolecules, Inc. (2009-2011), a chemistry eCommerce portal whose revenues grew from less than $500,000 to over $20 million; and a director of Penwest Pharmaceuticals Co. (2010), where he was a director nominee of an activist investor and the company was sold at ~3x its share price in less than 1 year. Saiid's professional experience also includes serving as an executive of Intrexon Corporation, Senomyx, Inc., Pharmacopeia, Inc., Molecular Simulations, Inc., Symbolics, Inc. and Computervision Corporation. Additional directorships he has held in the industry include Immune Therapeutics, Inc., Exemplar Pharma, LLC and Ambit Biosciences Corporation.
We strongly believe that the Company's stockholders will benefit from the addition of Messrs. Sargen, Scanlan and Zarrabian to the Board and we look forward to providing stockholders with an alternative to the status quo at the upcoming 2017 Annual Meeting.
Regards,
John S. Stafford III
RONIN TRADING, LLC
Stephen White
SW INVESTMENT MANAGEMENT LLC
CERTAIN INFORMATION CONCERNING THE PARTICIPANTS
Ronin Trading, LLC, together with the other participants named herein (collectively, "Ronin"), intends to file a preliminary proxy statement and an accompanying proxy card with the Securities and Exchange Commission ("SEC") to be used to solicit votes for the election of its slate of three highly qualified director nominees at the 2017 annual meeting of stockholders Peregrine Pharmaceuticals, Inc., a Delaware corporation (the "Company").
RONIN STRONGLY ADVISES ALL STOCKHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEB SITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST.
The participants in the solicitation are Ronin Trading, LLC ("Ronin Trading"), John S. Stafford, III, SWIM Partners LP ("SWIM Partners"), SW Investment Management LLC ("SW Management"), Stephen White, Gregory P. Sargen, Brian W. Scanlan and Saiid Zarrabian.
As of the date hereof, Ronin Trading directly beneficially owned 3,310,651 shares of the Company's common stock, $0.001 par value per share ("Common Stock"), including 137,260 shares of Common Stock that may be acquired upon the conversion of 115,299 shares of the Company's 10.50% Series E Convertible Preferred Stock, $0.001 par value per share ("Series E Preferred Stock"). Mr. Stafford, as the Manager of Ronin Trading, may be deemed to beneficially own the 3,310,651 shares of Common Stock beneficially owned directly by Ronin Trading. As of the date hereof, SWIM Partners directly beneficially owned 469,308 shares of Common Stock, including 10,333 shares of Common Stock that may be acquired upon the conversion of 8,680 shares of Series E Preferred Stock. As of the date hereof, an account separately managed by SW Management (the "SW Account") held 172,487 shares of Common Stock, including 3,714 shares of Common Stock that may be acquired upon the conversion of 3,120 shares of Series E Preferred Stock. SW Management, as the general partner and investment adviser of SWIM Partners and the investment adviser of the SW Account, may be deemed to beneficially own the 641,795 shares of Common Stock beneficially owned in the aggregate by SWIM Partners and held in the SW Account. Mr. White, as the Manager of SW Management, may be deemed to beneficially own the 641,795 shares of Common Stock beneficially owned in the aggregate by SWIM Partners and held in the SW Account. As of the date hereof, Messrs. Sargen, Scanlan and Zarrabian did not beneficially own any securities of the Company.
Investor Contact:
Stephen White
SW Investment Management LLC
(312) 765-7033
1 Source: Peregrine's Form 8-K filed on July 7, 2017, disclosing approximately 45 million shares outstanding (315 million pre-split).
2 Source: Conversation with Steven W. King and Paul J. Lytle.
3 Excludes indirect purchases made by Highlight Fund, LLC reported on Form 4 filings by Eric S. Swartz given no relationship is explained.
4 Source: Peregrine's SEC filings.
5 Source: SEC filings from Pfizer Inc., Merck & Co., Inc., Johnson & Johnson, Eli Lilly and Company and AbbVie Inc.
6 Source: Peregrine's SEC filings and Form 4 filings made by the NEOs. 93,467 figure is adjusted for reverse split and even includes 1,071 shares that could be acquired upon conversion of Series E Preferred Stock owned by NEO Mark R. Ziebell.
7 Source: Peregrine's SEC filings and Form 4 filings made by the NEOs. Adjusted for reverse split.
8 Number of shares and purchase prices not adjusted to reflect 1-for-7 reverse stock split that became effective on July 7, 2017 in discussion regarding Employee Stock Purchase Plan.
9 Max Sound share price and market cap as of July 12, 2017.
10 Patriot Scientific share price and market cap as of July 12, 2017.
11 Served as a director of Cryoport, Inc. from May 4, 2009 to March 1, 2012. Source: SEC filings; Bloomberg
12 Served as a director of ECOtality, Inc. from October 30, 2009 to December 15, 2011. Source: SEC filings; Bloomberg
View original content with multimedia:http://www.prnewswire.com/news-releases/ronin-trading-and-sw-investment-management-issue-letter-to-stockholders-of-peregrine-pharmaceuticals-300487810.html
SOURCE Ronin Trading, LLC and SW Investment Management LLC
Currently 0.00/512345
Rating: 0.0/5 (0 votes)
Email FeedsSubscribe via Email RSS FeedsSubscribe RSS
Comments
Please leave your comment:
Post Comment
More GuruFocus Links
Latest Guru Picks Value Strategies
Warren Buffett Portfolio Ben Graham Net-Net
Real Time Picks Buffett-Munger Screener
Aggregated Portfolio Undervalued Predictable
ETFs, Options Low P/S Companies
Insider Trends 10-Year Financials
52-Week Lows Interactive Charts
Model Portfolios DCF Calculator
RSS Feed Monthly Newsletters
The All-In-One Screener Portfolio Tracking Tool
GuruFocus has detected 3 Warning Signs with Peregrine Pharmaceuticals Inc $NAS:PPHM.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
Email Address
Password
Sign Up Now (Free)
Join the forum
to win a value investing book
Q2 2017 Hedge Fund Letters and Reports 5
Your Investment Checklist? 7
Factor affect share market 4
What is your favourite stock (if valuable was reasonable)? 8
Which cryptocurrency will be better to invest in after Bitcoin? 3
Collect data 2
Difference between book value and current share price 2
Global market impact 2
Eveyone who knows how can I download a personalized statement? 2
bitcoin 5
The History of Sears Predicts Nearly Everything Amazon Is Doing 1
Access the Forum!
?Performances of the stocks mentioned by PRNewswire
?User Generated Screeners
rael2222 Top A modificato
rael2222 dcf base earning yachtman pred
carlrevens test
arieldiaz29 High Quality
DBrizan 2017sep27 827p
Marty Fletcher Basic Search
jimshi values
Ken1940Noble dcf fcf undervalue predicabl
Ken1940Noble Buyback Undervalue predicable
cspunar Fund List B
?NAS:PPHM Price Chart
5D
3M
YTD
1Y
5Y
10Y
Oct '16
Jan '17
Apr '17
Jul '17
0
2.5
5
7.5
$3.14 (1y: +5%)
?Guru News
Wally Weitz Podcast Interview Transcript by Holly LaFon
7 Underperforming Stocks in Gurus' Portfolios by Tiziano Frateschi
Research Affiliates: Ignoring Starting Yields—Nabbing This 'Usual Suspect' in Poor Investment Outcomes by Holly LaFon
Worthington Industries Slides on Earnings Miss by Sydnee Gatewood
?Value Ideas
Sabby Management, Llc Buys Tesaro Inc, United Therapeutics Corp, Seattle Genetics Inc, Sells Bristol-Myers Squibb Company, Amgen Inc, Ionis Pharmaceuticals Inc by insider
7 Underperforming Stocks in Gurus' Portfolios by Tiziano Frateschi
Bill Ackman Buys Automatic Data Processing Inc, The Howard Hughes Corp, Sells Air Products & Chemicals Inc, Mondelez International Inc by insider
6 Undervalued Stocks Growing Earnings by Tiziano Frateschi
?Guru Interviews
Wally Weitz Podcast Interview Transcript by Holly LaFon
Interview With Star Investor Wally Weitz: GuruFocus Podcast Ep. 6 by Holly LaFon
Top Investor Joel Tillinghast to Appear on GuruFocus Podcast, With Reader Q&A by Holly LaFon
Wally Weitz to Join GuruFocus for Podcast by Holly LaFon
?Top Ranked Articles
These Unfortunate Facts Ensure Deep Value Will Outperform by Evan Bleker
What Can We Do Now? by Grahamites
Howard Marks Responds to Critics With Memo: 'Yet Again?' by Holly LaFon
In the Long Run, a High-Growth Stock Has to Be a High Return on Capital Stock by Geoff Gannon
?You May Also Like
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Peregrine Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
Ronin Trading and SW Investment Management Respond to Recent Announcements by Peregrine Pharmaceuticals
Ronin Trading and SW Investment Management Issue Letter to Employees of Peregrine Pharmaceuticals
Chemetall receives Airbus Best Performer Award at the Airbus Supplier Conference Awards in Tianjin, China
CGG: successfully completes first full-scale TopSeis survey in Barents Sea
Exactly, so anyone that associates with these scumbags you really have to think about.
Someone should be digging up puzzle pieces or using Watson to stir up some dirt.
But they wont
Im going to be serious here.
PPHM is hiring new peeps to fill the holes in BOD.
If its you and someone comes along and offers you a ton of cash and options you would be hard pressed to refuse.
You do your homework and see that they have done nothing for SH for 15 years and keep getting paid.
Why in the world would anyone turn this down.
They have more access to people in the business to find out how this BOD works and I think just like Garnick, they hear the cash register.
SCUMBAGS
They would never do that, they are as upfront as can be with the mushroom holders I mean shareholders.
They never keep them in the dark. I am sure they are just trying to figure out how much to cut their salaries.
Last I heard they were talking 90%
What list do I file it to?
They are getting overloaded.
SOON?
To The Moon?
Imminent?
Im going to have to clean these files soon.
I think people coming either get a free NASA rocket or Corningwear bowl for just stopping by. Interesting times ahead. Soon is right around the corner. Just a couple more puzzle pieces and tree shaking.
Just shaking the tree, guys that trust the process will reap the rewards.
Buy more at these prices it will make you look like a genius when the ship comes in.
I saw it in their eyes at the ASM. Well I wasnt there but many here were, and told us about it.
Any idea why they had to have security guards last time?
Was Janet Bleeker lurking in the bushes?
Just wait till a BP blinks and you will see astronomical value from the many collaborations going on unnoticed.
These guys dont have time to do their day jobs trying to keep up with their night work.
Ok so some people are leaving PPHM and new ones are coming in, it just mean they can do that and pay the new people by firing the 60 workers that did anything there.
Isnt it better to have more fat at the top than have people that maybe held the place together.
How else would they fight off Ronin?
Its imminent that we will see 2/300 a share and 2/3 forward splits.
This is the Microsoft of Biotechs.
If you are like us longs here, you bought in at the right time every time and we are still at 60 cents a share in our investment.
Thats the short of it.
Its the only reasonable conclusion in the world.
The family put pressure on him, Janet Bleeker was stalking him at Starbucks while he got his double latte half cream.
Puzzle pieces are adding up, not hard to see what going on here.
Im still waiting for the first BP to blink and mention PS .
Imminent and astronomical all in one boat.
Keep up the good work.
Problem is BP isnt interested, Ronin is the only one that is.
They will be when Ronin boots the clowns out.
KU, with thinking logical like that you will never make it long term in this stock.
You have to think about the FAMILY, Puzzle pieces and millions of collaborations that include Nasa and Corningwear.
This is the Microsoft Of Biotechs and Ronin is trying to steal it.
Im surprised the GSK, Roche, Abbott, Pfizer and others are letting this happen when they all need PS.
8.8 stake and no one is out bidding them.
I guess thats why its called THE PEARL
If the IP is so great why is RONIN the only one in the game?
You will hear from Ronin, and when you do it wont be something the scum bags can steal and pretend they thought up.
Ronin gave them a bone, but it will be their last one.
Time will show this BOD out the doors.
Its good that the BOD didnt lose a ton on the splits.
The FAMILY may still be buying in at these low prices.
What gets me is how bad some portray Ronin for wanting to steal the IP for nothing.
Its telling me 2 things.
Either Ronin is really really really smart or that all the BPs are dumb as hell.
Out of all the possible people in the world Ronin are the only ones to see the ASTRONOMICAL value of this and BPS are just sitting back and letting this happen?
It Imminent just as NO REVERSE SPLIT was.
Probably is what you say, I say they will add more value in 6 months than this BOD has added in 15.
Its good you admit the SH have been getting screwed for so long from the BOD.
Let me try it this way and see if I understand
Lets say you had 100000 shares at 50 cents cost average 50k
They went from 100000 to 20000 with the 1/5 RS
Now they did a 1/7 and they are at 2857 that is now 8571 bucks
I can see why you are so worried if Ronin sells at 10 a share
28500 with a investment of 50k after 20 years
Hoping years ago would be 200/300 a share at 100k shares
You would end up 22k in the hole.
Am I close?
The boards opinion always was 2/300 a share and 2/3 forwards splits under the current BOD so I doubt it will change with Ronin.
They did say in their letter that they were in it for the long haul.
I finally figured this out from following the puzzle pieces.
JB wasnt Janet Bleeker it was John Bonfiglio
Thats why her name was changed and profiles gone.
Thorpe was getting close and they had him killed.
We have to have the body exhumed and I dont understand why Ronin wont do this?
BP is paying to keep the IP off the market so it doesnt take over and become the Microsoft of Biotechnology.
BURN THE WHITE CARD UNLESS JB became a mailman and opened the RED ones and bleached them and resealed the letters.
More puzzle pieces to come.
Did anyone see if you spell Ronin backwards you get Ninor?
Coincidence or not? Follow the money
Only if they are scoundrels. ??????????????
What would you call the current BOD ?
Everyone calls them scumbags for a reason.
Ronin has done nothing but raised the SP and brought out truth about the BOD.
Read Ronins letter, they said they were not here for the short time.
DESTROY THE WHITE PROXY CARD
What you are saying is that PPHM has the Microsoft of Biotechs and would rather keep it sealed instead of letting everyone know how great it is?
The board is choking off their own blood supply?
Thats what makes sense.
I am in PA, I was fine but brother is in Marco and his house may be totaled.
Did I read it right what what I saw here?
That Ronin stole PPHM BOD ideas?
That may be the funniest thing I have heard in years after the RS is a neutral.
BURN THE WHITE CARD
IFU, been busy, hurricane stuff.
Im not sure what to do with the white proxy card?
Any ideas?
Steve White told me dont believe what you read on message boards.
Anyone can make something up.
You can answer me one question, Did it take both parties to OK the botched trial papers to be sealed?
James follow the money
Tell me again how the RS was a neutral?
How about the current BOD experts?
So PPHM had earth shattering news and they agreed to seal the outcome?
Thats like throwing a lottery ticket away isnt it?
Didnt both sides agree to seal it?
Your theory is JB got paid off , so did the BOD get paid off also?
Define soon for me, is it before or after imminent?
Go back and check the volume, as you must know there was none until Ronin jumped into the game. Tell me what news you would expect? Buyout? BOD gets lost in the Bermuda Triangle? Sunrise update? Janet Bleekers marriage certificate?.. No one will go near this until the BOD is gone . Ronin told the investment world what they thought about them and they couldnt respond. Its not hard to answer if they are false statements but we see they just refuse to answer. SILENCE IS DEAFENING.
It was rational just one you didnt want to hear and thought someone would come to your aid.
The Plll Sunrise trail was likely initiated to give an air of legitimacy just to sell ATM and raise cash for bloated staff and salaries.
The Pll "sabotage" only helped to blur the lines and gain sympathy from the FDA allowing a Plll. Perhaps pricey consultant Garnick got the job done?? Lots of money was made on the short side as the stock became margin-able just prior to Black Monday press release. AbbVie reportedly caught wind and ran and Feuerstein knew all along Bavi was a bust.
The PP crack legal team did not prepare vendor contracts correctly, did not pursue "intent", leaving shareholders dead in the water. King& Co. did not even bother to explain the botched trial to their poor destroyed shareholders. To make matters worse "leadership" agreed to have the records sealed so as to never get to the bottom of anything. For it they all collected hundred of thousands of dollars in salaries and bonuses.
Sunrise fizzled out with no valuable data and a pricey Head of Reg Affair consultant who turned out to be working with another biotech company making real headway.
And some folks still want to give "leadership" a chance. ...
You just can't make this stuff up!
You asked this same question before.
You answer comes from not anyone trusting this BOD.
You dont think BPs and the market read the same letters that Ronin sent out and never responded to?
Ronin never lied in their letter.
PPHM couldnt respond.
Until the scumbags are gone, this is tanking.
I guess all the BP are waiting for the other one to blink?
Tons of collaborations but none mentioned except by you.
Is Corning still in it?
Nasa?
I find it very hard that no one but 5 guys on Ihub know this stuff.
I am sure BP just over look this.
BOD will be gone soon. Some will be out of jobs. If you get my drift.
Do you know if CP has given his opinion on Ronins proxy?
Did they mention Cotara or Oncolym?
Please show me where he said worthless .
You never show your cards, why would they tell these scumbags what they know?
Do you turn your cards over playing poker?
I would be a ton happier if PPHM BOD ever told the SH what was going on.
Didnt they have to be pressured before from what was posted on a message board?
Why have they not answered Ronins 2 letters?
Check out Swartzs batting average in Ronins last letter.
They may not let Ronin speak at this meeting but I am sure they will speak at the next one.